What do you mean? This is probably the least hyped bio that I have ever seen compared to its potential. Maybe some of the Yahoo MB followers hype a bit too much, but nobody of consequence reads these boards or makes major investment decisions based on what is written here. The news coming out of the company itself is relatively modest and to the point. The company itself does not hype its own achievements which is refreshing in this field. Only Tanzi has been fairly vocal, but also not hyping, just maybe excited about what he thinks may be coming. I don't believe PRAN is followed much by regular folks only a couple speculators are in this. Some investment firms may now be catching wind of it and the potential here. If this drug works, the news that will hit the wires will travel the world. It will be the biggest bio tech news in decades. If it doesn't work it will go out with a wimper and nobody will have noticed.
If this is crazy hype, explain why. There is accumulating evidence on PBT2's mechanism of action, some done by Prana scientists, some done by others. I don't understand why you think that using PBT2 for metal dyshomeostasis would be, in your words, "a big risk." Of all things, PBT2 has not shown any safety concerns, so it is not a risk at all. Your comment about amyloid decreasing having no significance is simplistic. PBT2's effect is on detoxification and neuronal restoration -- so tell us why that is not significant.
I am beginning to see that. The literature doesn't look all that compelling to me and this approach has already failed once. I think the primary safety endpoint will be reached, and perhaps some AB lowering, but I have my doubts about the significance of motor skills improvement and that's all that matters in this case.
Sentiment: Strong Sell